NASDAQ:AKBA

Akebia Therapeutics News Headlines

$3.67
-0.02 (-0.54 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.63
$3.74
50-Day Range
$2.83
$3.69
52-Week Range
$2.09
$13.71
Volume1.92 million shs
Average Volume5.15 million shs
Market Capitalization$587.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Akebia Therapeutics (NASDAQ AKBA) News Headlines Today

SourceHeadline
Steven C. Gilman Sells 4,567 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) StockSteven C. Gilman Sells 4,567 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock
americanbankingnews.com - June 9 at 5:48 PM
Reflecting on Akebia Therapeutics (NASDAQ:AKBA) Share Price Returns Over The Last YearReflecting on Akebia Therapeutics' (NASDAQ:AKBA) Share Price Returns Over The Last Year
finance.yahoo.com - June 8 at 7:48 AM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Buy" by AnalystsAkebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - June 4 at 3:30 AM
FDA accepts Akebias vadadustat NDA for reviewFDA accepts Akebia's vadadustat NDA for review
seekingalpha.com - June 4 at 12:23 AM
Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021
finance.yahoo.com - June 3 at 9:22 AM
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Down to $3.41Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Down to $3.41
americanbankingnews.com - June 2 at 10:55 AM
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Up to $3.51Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Up to $3.51
americanbankingnews.com - June 1 at 11:14 AM
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on DialysisAkebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
finance.yahoo.com - June 1 at 9:06 AM
Comparing Akebia Therapeutics (NASDAQ:AKBA) & Zealand Pharma A/S (NASDAQ:ZEAL)Comparing Akebia Therapeutics (NASDAQ:AKBA) & Zealand Pharma A/S (NASDAQ:ZEAL)
americanbankingnews.com - May 31 at 5:02 AM
Akebia Therapeutics, Inc.s (NASDAQ:AKBA) CEO Might Not Expect Shareholders To Be So Generous This YearAkebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Might Not Expect Shareholders To Be So Generous This Year
nasdaq.com - May 27 at 2:44 AM
Satter Management Co., L.p. Buys Aileron Therapeutics IncSatter Management Co., L.p. Buys Aileron Therapeutics Inc
uk.finance.yahoo.com - May 20 at 8:50 AM
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2021 Results - Earnings Call TranscriptAkebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:30 AM
Recap: Akebia Therapeutics Q1 EarningsRecap: Akebia Therapeutics Q1 Earnings
benzinga.com - May 10 at 9:07 AM
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company MilestonesAkebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
finance.yahoo.com - May 10 at 9:07 AM
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For ArdelyxThe Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
markets.businessinsider.com - April 29 at 8:39 AM
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney DiseaseNew England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
finance.yahoo.com - April 28 at 7:45 PM
Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business HighlightsAkebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights
finance.yahoo.com - April 28 at 9:44 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 26 at 9:09 AM
What Type Of Shareholders Own The Most Number of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares?What Type Of Shareholders Own The Most Number of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares?
finance.yahoo.com - April 24 at 9:20 AM
Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare ConferenceAkebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 12 at 8:49 AM
Akebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKDAkebia (AKBA) Files NDA for Vadadustat for Anemia Due to CKD
finance.yahoo.com - March 31 at 2:14 PM
Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on DialysisAkebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
finance.yahoo.com - March 30 at 7:51 AM
AKBA Apr 2021 3.500 callAKBA Apr 2021 3.500 call
in.finance.yahoo.com - March 25 at 10:16 AM
Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical MeetingsAkebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
finance.yahoo.com - March 25 at 10:16 AM
AKBA May 2021 2.500 callAKBA May 2021 2.500 call
in.finance.yahoo.com - March 25 at 12:47 AM
Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in JapanAkebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan
finance.yahoo.com - March 24 at 9:46 AM
Akebia Therapeutics Celebrates World Kidney Day and National Kidney MonthAkebia Therapeutics Celebrates World Kidney Day and National Kidney Month
finance.yahoo.com - March 11 at 8:52 AM
Looking Into Akebia Therapeuticss Return On Capital EmployedLooking Into Akebia Therapeutics's Return On Capital Employed
finance.yahoo.com - March 2 at 2:46 PM
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call TranscriptAkebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 6:15 PM
Why Akebia Therapeutics Stock Is Plunging TodayWhy Akebia Therapeutics Stock Is Plunging Today
finance.yahoo.com - February 25 at 3:43 PM
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business UpdatesAkebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates
finance.yahoo.com - February 25 at 10:43 AM
Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of DirectorsAkebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors
finance.yahoo.com - February 18 at 1:49 PM
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business HighlightsAkebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights
finance.yahoo.com - February 8 at 8:35 AM
Return On Capital Employed Overview: Akebia TherapeuticsReturn On Capital Employed Overview: Akebia Therapeutics
benzinga.com - January 29 at 1:01 PM
Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 ConferenceAkebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference
finance.yahoo.com - January 6 at 8:11 AM
Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceAkebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:48 AM
Is AKBA A Good Stock To Buy Now?Is AKBA A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 4:34 PM
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock OptionsImplied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options
finance.yahoo.com - December 16 at 11:34 AM
AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via TelehealthAkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth
finance.yahoo.com - December 9 at 9:02 AM
The Play On Akebia NowThe Play On Akebia Now
seekingalpha.com - November 29 at 8:14 AM
Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare ConferenceAkebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 24 at 12:03 PM
News for Akebia Therapeutics IncNews for Akebia Therapeutics Inc
markets.businessinsider.com - November 19 at 11:38 AM
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloittes 2020 Technology Fast 500™Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
finance.yahoo.com - November 18 at 12:59 PM
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical JournalAkebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal
finance.yahoo.com - November 16 at 8:59 AM
Is the Options Market Predicting a Spike in Akebia (AKBA) Stock?Is the Options Market Predicting a Spike in Akebia (AKBA) Stock?
finance.yahoo.com - November 12 at 11:45 AM
Some Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Just Made A Major Cut To Next Years EstimatesSome Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Just Made A Major Cut To Next Year's Estimates
nasdaq.com - November 10 at 10:27 AM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next YearAkebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year
finance.yahoo.com - November 10 at 10:27 AM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Cutting Their Estimates: Heres What You Need To KnowAkebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
nasdaq.com - November 7 at 8:14 AM
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their EstimatesAkebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates
finance.yahoo.com - November 7 at 8:14 AM
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call TranscriptAkebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 6 at 2:26 PM
This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.